MSLN and malignant pleural mesothelioma: Mesothelin and osteopontin have showed early promise for early detection of asbestos-related mesothelioma; when measuring soluble mesothelin-related peptide (SMRP) levels in malignant pleural mesothelioma as well as benign pleural pathology, SMRP was able to distinguish between asbestos exposed and naïve patients (36).